News & Updates

In the pivotal phase III ZIRCON study, PET/CT imaging with ⁸⁹Zr-DFO-girentuximab, an investigational imaging agent, demonstrated potential in the noninvasive identification of clear-cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IDRM).

Adding dostarlimab or pembrolizumab to standard first-line (1L) chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, two phase III trials have shown.

Eating nuts may not be beneficial in terms of reducing the risk of total, advanced, nonadvanced, and fatal prostate cancer, according to the results of a meta-analysis.

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, improves progression-free survival (PFS) and responses vs standard regimens in patients with triple class–exposed relapsed and refractory multiple myeloma (R/R MM), the phase III KarMMa-3 trial has shown.

In patients with early rectal cancer (ERC), endoscopic submucosal dissection (ESD) appears safer and is associated with shorter hospital stay than transanal endoscopic microsurgery (TEM), results of a recent study have shown.

The angiotensin receptor neprilysin inhibitor sacubitril/valsartan, used for heart failure, appears to have potent effects on 24‐hour blood pressure (BP) in Japanese patients with mild‐to‐moderate hypertension and in the subgroup of those with nondipping BP pattern, as shown in a study.

The use of hysteroscopy for surgical management of incomplete spontaneous abortion in individuals who intend to conceive again neither leads to more subsequent births nor shows a better safety profile compared with vacuum aspiration, according to the results of the HY-PER trial.